Omega oils and fish lower the risk of AMD in women.

Article

Regular intake of omega-3 fatty acids and fish is linked to a significant reduction in the risk of AMD, according to a study published in the Archives of Ophthalmology.

Regular intake of omega-3 fatty acids and fish is linked to a significant reduction in the risk of AMD, according to a study published in the Archives of Ophthalmology.

A team led by Dr William G. Christen, Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, asked 38 022 women to complete a food-frequency questionnaire. The outcome measures were best-corrected visual acuity to 20/30 or worse based on self-report confirmed by medical record review.

The results, after 10 years of follow-up, confirmed that women in the highest percentile of docosahexaenoic acid consumption, compared with those in the lowest, had a multivariate-adjusted relative risk of AMD of 0.62. For eicosapentaenoic the risk of AMD was 0.66.

The consumption of omega-3 fatty acids such as docosahexaenoic acid and eicosapentaenoic acid could be beneficial in the primary prevention of AMD.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.